Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferroptosis via regulating SCD1-mediated unsaturated fatty acid metabolism.


Journal

Biology direct
ISSN: 1745-6150
Titre abrégé: Biol Direct
Pays: England
ID NLM: 101258412

Informations de publication

Date de publication:
20 Nov 2023
Historique:
received: 28 06 2023
accepted: 02 10 2023
medline: 27 11 2023
pubmed: 21 11 2023
entrez: 21 11 2023
Statut: epublish

Résumé

Pancreatic cancer is a malignancy with high mortality. Once diagnosed, effective treatment strategies are limited and the five-year survival is extremely poor. Recent studies have shown that zinc finger proteins play important roles in tumorigenesis, including pancreatic cancer. However, it remains unknown on the clinical significance, function and underlying mechanisms of zinc finger protein 488 (ZNF488) during the development of pancreatic cancer. The clinical relevance of ZNF488 and stearoyl-CoA desaturase 1 (SCD1) was examined by analyzing the data from The Cancer Genome Atlas (TCGA) and immunohistochemical staining of the tissue microarray. Gain-of-function and loss-of-function experiments were performed by transfecting the cells with overexpressing lentivirus and siRNAs or shRNA lentivirus, respectively. The function of ZNF488 in pancreatic cancer was assessed by CCK8, colony formation, EdU staining, PI/Annexin V staining and xenografted tumorigenesis. Chip-qPCR assay was conducted to examine the interaction between ZNF488 and the promoter sequence of SCD1. Transcription activity was measured by dual luciferase reporter assay. mRNA and protein expression was detected by qRT-PCR and immunoblotting experiment, respectively. Fatty acid was quantified by gas chromatography mass spectrometry. ZNF488 was overexpressed in pancreatic cancer samples compared with normal tissues. High expression of ZNF488 predicted the poor prognosis of the patients. In vitro, ZNF488 upregulation contributed to the EuU cooperation, proliferation and colony formation of MIAPaCa-2 and PANC-1 cells. Based on PI/Annexin V and trypan blue staining results, we showed that ZNF488 suppressed the ferroptosis and apoptosis of pancreatic cancer cells. Mechanistically, ZNF488 directly interacted with the promoter sequence of SCD1 gene and promoted its transcription activity, which resulted in enhanced palmitoleic and oleic acid production, as well as the peroxidation of fatty acid. In vivo, ZNF488 overexpression promoted the xenograted tumorigenesis of PANC-1, which was reversed by SCD1 knockdown. Importantly, combination of erastin and SCD1 inhibitors A939572 completely blunted the growth of ZNF488 overexpressed MIAPaCa-2 and PANC-1 cells. Usage of A939572 or erastin recovered the sensitivity of pancreatic cancer cells to the treatment of gemcitabine. Lastly, we found a positive correlation between ZNF488 and SCD1 in pancreatic cancer patients based on TCGA and immunohistochemical staining results. Overexpression of ZNF488 suppresses the ferroptosis and apoptosis to support the growth and tumorigenesis of pancreatic cancer through augmentation of SCD1-mediated unsaturated fatty acid metabolism. Combination of SCD1 inhibitors, ferroptosis inducers or gemcitabine could be applied for the treatment of pancreatic cancer with overexpression of ZNF488.

Sections du résumé

BACKGROUND BACKGROUND
Pancreatic cancer is a malignancy with high mortality. Once diagnosed, effective treatment strategies are limited and the five-year survival is extremely poor. Recent studies have shown that zinc finger proteins play important roles in tumorigenesis, including pancreatic cancer. However, it remains unknown on the clinical significance, function and underlying mechanisms of zinc finger protein 488 (ZNF488) during the development of pancreatic cancer.
METHODS METHODS
The clinical relevance of ZNF488 and stearoyl-CoA desaturase 1 (SCD1) was examined by analyzing the data from The Cancer Genome Atlas (TCGA) and immunohistochemical staining of the tissue microarray. Gain-of-function and loss-of-function experiments were performed by transfecting the cells with overexpressing lentivirus and siRNAs or shRNA lentivirus, respectively. The function of ZNF488 in pancreatic cancer was assessed by CCK8, colony formation, EdU staining, PI/Annexin V staining and xenografted tumorigenesis. Chip-qPCR assay was conducted to examine the interaction between ZNF488 and the promoter sequence of SCD1. Transcription activity was measured by dual luciferase reporter assay. mRNA and protein expression was detected by qRT-PCR and immunoblotting experiment, respectively. Fatty acid was quantified by gas chromatography mass spectrometry.
RESULTS RESULTS
ZNF488 was overexpressed in pancreatic cancer samples compared with normal tissues. High expression of ZNF488 predicted the poor prognosis of the patients. In vitro, ZNF488 upregulation contributed to the EuU cooperation, proliferation and colony formation of MIAPaCa-2 and PANC-1 cells. Based on PI/Annexin V and trypan blue staining results, we showed that ZNF488 suppressed the ferroptosis and apoptosis of pancreatic cancer cells. Mechanistically, ZNF488 directly interacted with the promoter sequence of SCD1 gene and promoted its transcription activity, which resulted in enhanced palmitoleic and oleic acid production, as well as the peroxidation of fatty acid. In vivo, ZNF488 overexpression promoted the xenograted tumorigenesis of PANC-1, which was reversed by SCD1 knockdown. Importantly, combination of erastin and SCD1 inhibitors A939572 completely blunted the growth of ZNF488 overexpressed MIAPaCa-2 and PANC-1 cells. Usage of A939572 or erastin recovered the sensitivity of pancreatic cancer cells to the treatment of gemcitabine. Lastly, we found a positive correlation between ZNF488 and SCD1 in pancreatic cancer patients based on TCGA and immunohistochemical staining results.
CONCLUSION CONCLUSIONS
Overexpression of ZNF488 suppresses the ferroptosis and apoptosis to support the growth and tumorigenesis of pancreatic cancer through augmentation of SCD1-mediated unsaturated fatty acid metabolism. Combination of SCD1 inhibitors, ferroptosis inducers or gemcitabine could be applied for the treatment of pancreatic cancer with overexpression of ZNF488.

Identifiants

pubmed: 37986084
doi: 10.1186/s13062-023-00421-6
pii: 10.1186/s13062-023-00421-6
pmc: PMC10658979
doi:

Substances chimiques

Annexin A5 0
Fatty Acids 0
Gemcitabine 0
Fatty Acids, Unsaturated 0
SCD1 protein, human EC 1.14.19.1
Stearoyl-CoA Desaturase EC 1.14.19.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

77

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA022701
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Biomolecules. 2022 May 15;12(5):
pubmed: 35625633
Histol Histopathol. 2022 Dec 2;:18568
pubmed: 36537752
Comput Math Methods Med. 2021 Aug 3;2021:5549298
pubmed: 34394706
Cell Metab. 2020 Dec 1;32(6):920-937
pubmed: 33217331
Cell Death Dis. 2021 Sep 3;12(9):830
pubmed: 34480024
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Nat Cell Biol. 2019 May;21(5):579-591
pubmed: 30962574
Gastroenterology. 2013 May;144(5):1066-1075.e1
pubmed: 23376425
Cancer Res Treat. 2016 Jan;48(1):334-44
pubmed: 25779368
Nat Rev Clin Oncol. 2021 May;18(5):280-296
pubmed: 33514910
Theranostics. 2022 Apr 24;12(7):3534-3552
pubmed: 35547771
FEMS Microbiol Rev. 2021 May 5;45(3):
pubmed: 33175962
Biomark Res. 2022 Jan 9;10(1):2
pubmed: 35000617
Nature. 2015 Apr 2;520(7545):57-62
pubmed: 25799988
Redox Biol. 2021 Jan;38:101807
pubmed: 33271455
Cancers (Basel). 2022 May 13;14(10):
pubmed: 35626020
Cell Death Dis. 2021 Nov 13;12(11):1079
pubmed: 34775496
Adv Mater. 2019 Dec;31(51):e1904197
pubmed: 31595562
Int J Mol Sci. 2021 Aug 06;22(16):
pubmed: 34445164
Cell Prolif. 2021 May;54(5):e13031
pubmed: 33755268
Exp Cell Res. 2019 Jul 15;380(2):188-197
pubmed: 31026442
Redox Biol. 2022 Sep;55:102426
pubmed: 35963119
J Exp Clin Cancer Res. 2021 Aug 24;40(1):265
pubmed: 34429143
Sci Rep. 2019 Jun 21;9(1):9013
pubmed: 31227736
Nat Rev Cancer. 2022 Mar;22(3):131-142
pubmed: 34789870
Front Neurosci. 2021 Nov 18;15:760567
pubmed: 34867169
Cancer Manag Res. 2019 Jun 28;11:5871-5882
pubmed: 31303793
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):469-481
pubmed: 34089011
Tumour Biol. 2015 Jun;36(6):4133-41
pubmed: 25589463
Drug Des Devel Ther. 2019 Jul 02;13:2135-2144
pubmed: 31456633
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31189-31197
pubmed: 33229547
Asia Pac J Clin Oncol. 2022 Dec;18(6):506-514
pubmed: 35098656
Cell Rep. 2016 Dec 13;17(11):3062-3076
pubmed: 27974217
Signal Transduct Target Ther. 2020 Jun 30;5(1):108
pubmed: 32606298
J Cell Mol Med. 2019 Aug;23(8):4900-4912
pubmed: 31232522
Comput Math Methods Med. 2022 Jan 24;2022:4622877
pubmed: 35111235
FASEB J. 2019 Sep;33(9):10089-10103
pubmed: 31199678

Auteurs

Qifeng Xiao (Q)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Zhongmin Lan (Z)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Shuisheng Zhang (S)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Hu Ren (H)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Shunda Wang (S)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Peng Wang (P)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Lin Feng (L)

State Key Laboratory of Molecular Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Dan Li (D)

State Key Laboratory of Molecular Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Chengfeng Wang (C)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Xiaofeng Bai (X)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. baixiaofeng1973@163.com.

Jianwei Zhang (J)

Pancreatic and gastric surgery department, National Cancer Center/National clinical research center for cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. panchutong@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH